BICYCLE THERAPEUTICS PLC current report, 02 October 2020

Full document

Filing Overview

Bicycle Therapeutics plc filed a Form 8-K on October 2, 2020, reporting an update to its equity financing program under Item 8.01. The company is incorporated in England and Wales, and its ADSs trade on Nasdaq under the symbol BCYC.

Material Financing Update

  • The company filed a prospectus supplement for the potential sale of up to an additional $75.0 million of American Depositary Shares under its Controlled Equity Offering Sales Agreement dated June 5, 2020.
  • The offering may be conducted from time to time through Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. as sales agents.
  • The company is not obligated to sell any shares. Sales may be made through at-the-market transactions or other legally permitted methods, subject to customary conditions and company instructions.
  • The sales agents will receive a commission equal to 3.0% of aggregate gross proceeds from each sale, and the company will reimburse certain specified expenses.
  • Shares will be issued under the company’s effective Form S-3 registration statement, File No. 333-238996.

Financial Metrics and Liquidity

This filing does not provide revenue, profit, cash flow, margin, debt, cash balance, or other operating financial metrics. The potential offering could provide additional liquidity if shares are sold, but the filing does not state that any shares had been sold as of October 2, 2020 or quantify expected net proceeds.

Outlook, Risks, and Unusual Items

  • Any actual proceeds will depend on the timing, volume, and market prices of future ADS sales.
  • Issuance of ADSs may dilute existing shareholders.
  • The company’s obligation to pay commissions and certain expenses will reduce gross offering proceeds.
  • The filing is not itself an offer to sell or solicitation to buy securities; sales remain subject to applicable securities-law registration or qualification requirements.

Important Facts to Verify

  • Whether and when the company sells ADSs under the expanded $75.0 million capacity.
  • The aggregate gross and net proceeds raised, including commissions and expenses.
  • The number of ADSs issued and resulting shareholder dilution.
  • Use of proceeds and the effect on the company’s cash runway and funding requirements.
  • The full terms of the Sales Agreement and related legal opinion filed as Exhibits 1.1 and 5.1.